As of the 10th of February, Big Pharma shows the mean deviation of 1.32, and Risk Adjusted Performance of 0.1538. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Big Pharma, as well as the relationship between them.
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Big, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to Big
Big
Big Pharma's Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.
It's important to distinguish between Big Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Big Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Big Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Big Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Big Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Big Pharma.
0.00
11/12/2025
No Change 0.00
0.0
In 2 months and 31 days
02/10/2026
0.00
If you would invest 0.00 in Big Pharma on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Big Pharma Split or generate 0.0% return on investment in Big Pharma over 90 days. Big Pharma is related to or competes with Bankers Petroleum, Elysee Development, NMC Resource, and RE Royalties. Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc More
Big Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Big Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Big Pharma Split upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Big Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Big Pharma's standard deviation. In reality, there are many statistical measures that can use Big Pharma historical prices to predict the future Big Pharma's volatility.
Big Pharma appears to be not too volatile, given 3 months investment horizon. Big Pharma Split secures Sharpe Ratio (or Efficiency) of 0.15, which signifies that the company had a 0.15 % return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for Big Pharma Split, which you can use to evaluate the volatility of the firm. Please makes use of Big Pharma's mean deviation of 1.32, and Risk Adjusted Performance of 0.1538 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Big Pharma holds a performance score of 12. The firm shows a Beta (market volatility) of 0.24, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Big Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Big Pharma is expected to be smaller as well. Please check Big Pharma's total risk alpha, expected short fall, price action indicator, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether Big Pharma's price patterns will revert.
Auto-correlation
0.35
Below average predictability
Big Pharma Split has below average predictability. Overlapping area represents the amount of predictability between Big Pharma time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Big Pharma Split price movement. The serial correlation of 0.35 indicates that nearly 35.0% of current Big Pharma price fluctuation can be explain by its past prices.
Correlation Coefficient
0.35
Spearman Rank Test
0.44
Residual Average
0.0
Price Variance
0.11
Big Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Big Pharma technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Big Pharma trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...
Big Pharma Split Technical Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Normalized Average True Range is used to analyze tradable apportunities for Big Pharma Split across different markets.
About Big Pharma Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Big Pharma Split on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Big Pharma Split based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Big Pharma Split price pattern first instead of the macroeconomic environment surrounding Big Pharma Split. By analyzing Big Pharma's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Big Pharma's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Big Pharma specific price patterns or momentum indicators. Please read more on our technical analysis page.
Most technical analysis of Big help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Big from various momentum indicators to cycle indicators. When you analyze Big charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Big Pharma February 10, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Big stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.